362 related articles for article (PubMed ID: 31470785)
41. Toll-like receptor agonists induce apoptosis in mouse B-cell lymphoma cells by altering NF-κB activation.
Arunkumar N; Liu C; Hang H; Song W
Cell Mol Immunol; 2013 Jul; 10(4):360-72. PubMed ID: 23727784
[TBL] [Abstract][Full Text] [Related]
42. CpG ODN mimicking CpG rich region of myxosporean Myxobolus supamattayai stimulates innate immunity in Asian sea bass (Lates calcarifer) and defense against Streptococcus iniae.
U-Taynapun K; Chirapongsatonkul N; Itami T; Tantikitti C
Fish Shellfish Immunol; 2016 Nov; 58():116-124. PubMed ID: 27629917
[TBL] [Abstract][Full Text] [Related]
43. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.
Ilvesaro JM; Merrell MA; Li L; Wakchoure S; Graves D; Brooks S; Rahko E; Jukkola-Vuorinen A; Vuopala KS; Harris KW; Selander KS
Mol Cancer Res; 2008 Oct; 6(10):1534-43. PubMed ID: 18922969
[TBL] [Abstract][Full Text] [Related]
44. Structural basis for species-specific activation of mouse Toll-like receptor 9.
Ishida H; Ohto U; Shibata T; Miyake K; Shimizu T
FEBS Lett; 2018 Aug; 592(15):2636-2646. PubMed ID: 29961984
[TBL] [Abstract][Full Text] [Related]
45. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.
Schlaepfer E; Audigé A; von Beust B; Manolova V; Weber M; Joller H; Bachmann MF; Kundig TM; Speck RF
J Virol; 2004 Nov; 78(22):12344-54. PubMed ID: 15507621
[TBL] [Abstract][Full Text] [Related]
46. The expression and function of Toll-like receptors 3 and 9 in human colon carcinoma.
Nojiri K; Sugimoto K; Shiraki K; Tameda M; Inagaki Y; Kusagawa S; Ogura S; Tanaka J; Yoneda M; Yamamoto N; Okano H; Takei Y; Ito M; Kasai C; Inoue H; Takase K
Oncol Rep; 2013 May; 29(5):1737-43. PubMed ID: 23467704
[TBL] [Abstract][Full Text] [Related]
47. CpG ODN 1668 as TLR9 agonist mediates humpback grouper (Cromileptes altivelis) antibacterial immune responses.
Chen X; Zhang P; Li P; Wang G; Li J; Wu Y; Cao Z; Zhou Y; Sun Y
Fish Shellfish Immunol; 2023 Jul; 138():108839. PubMed ID: 37207883
[TBL] [Abstract][Full Text] [Related]
48. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens.
Andersen JM; Al-Khairy D; Ingalls RR
Biol Reprod; 2006 May; 74(5):824-31. PubMed ID: 16421230
[TBL] [Abstract][Full Text] [Related]
49. Phosphodiester backbone of the CpG motif within immunostimulatory oligodeoxynucleotides augments activation of Toll-like receptor 9.
Pohar J; Lainšček D; Kunšek A; Cajnko MM; Jerala R; Benčina M
Sci Rep; 2017 Nov; 7(1):14598. PubMed ID: 29097808
[TBL] [Abstract][Full Text] [Related]
50. TLR9 mediates S. aureus killing inside osteoblasts via induction of oxidative stress.
Mohamed W; Domann E; Chakraborty T; Mannala G; Lips KS; Heiss C; Schnettler R; Alt V
BMC Microbiol; 2016 Oct; 16(1):230. PubMed ID: 27716055
[TBL] [Abstract][Full Text] [Related]
51. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells.
Marshak-Rothstein A; Busconi L; Lau CM; Tabor AS; Leadbetter EA; Akira S; Krieg AM; Lipford GB; Viglianti GA; Rifkin IR
J Endotoxin Res; 2004; 10(4):247-51. PubMed ID: 15373969
[TBL] [Abstract][Full Text] [Related]
52. Novel immunostimulatory phosphodiester oligodeoxynucleotides with CpT sequences instead of CpG motifs.
Kim D; Jung J; Lee Y; Kwon HJ
Mol Immunol; 2011 Jul; 48(12-13):1494-504. PubMed ID: 21529949
[TBL] [Abstract][Full Text] [Related]
53. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM
Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717
[TBL] [Abstract][Full Text] [Related]
54. CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo.
Knuefermann P; Baumgarten G; Koch A; Schwederski M; Velten M; Ehrentraut H; Mersmann J; Meyer R; Hoeft A; Zacharowski K; Grohé C
Respir Res; 2007 Oct; 8(1):72. PubMed ID: 17925007
[TBL] [Abstract][Full Text] [Related]
55. Lipid Nanoparticle Delivery Alters the Adjuvanticity of the TLR9 Agonist CpG by Innate Immune Activation in Lymphoid Tissue.
Zhong Z; Chen Y; Deswarte K; Lauwers H; De Lombaerde E; Cui X; Van Herck S; Ye T; Gontsarik M; Lienenklaus S; Sanders NN; Lambrecht BN; De Koker S; De Geest BG
Adv Healthc Mater; 2023 Dec; 12(32):e2301687. PubMed ID: 37772637
[TBL] [Abstract][Full Text] [Related]
56. Synthetic Human TLR9-LRR11 Peptide Attenuates TLR9 Signaling by Binding to and thus Decreasing Internalization of CpG Oligodeoxynucleotides.
Pan X; Li B; Kuang M; Liu X; Cen Y; Qin R; Ding G; Zheng J; Zhou H
Int J Mol Sci; 2016 Feb; 17(2):242. PubMed ID: 26907260
[TBL] [Abstract][Full Text] [Related]
57. Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape formation.
Nishikawa M; Matono M; Rattanakiat S; Matsuoka N; Takakura Y
Immunology; 2008 Jun; 124(2):247-55. PubMed ID: 18217956
[TBL] [Abstract][Full Text] [Related]
58. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
59. Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity.
Putta MR; Zhu FG; Wang D; Bhagat L; Dai M; Kandimalla ER; Agrawal S
Bioconjug Chem; 2010 Jan; 21(1):39-45. PubMed ID: 20020767
[TBL] [Abstract][Full Text] [Related]
60. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells.
Römmler F; Hammel M; Waldhuber A; Müller T; Jurk M; Uhlmann E; Wagner H; Vollmer J; Miethke T
PLoS One; 2015; 10(2):e0116703. PubMed ID: 25695778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
